|
William J. Slichenmyer, M.D. joined Merrimack in July 2007 as Senior Vice President & Chief Medical Officer. From 2005 to 2007, Dr. Slichenmyer held the position of Vice President of Regulatory Affairs for all therapeutic areas at Pfizer, Inc. While he was in that role, Pfizer won approval for some notable products including Sutent (cancer), Exubera (diabetes), Chantix (smoking cessation) and Macugen (macular degeneration). Dr. Slichenmyer's role at Pfizer from 2000-2005 was Vice President and Worldwide Therapeutic Area Head for Oncology Clinical Development. Prior to Pfizer, Dr. Slichenmyer held senior drug development positions at Bristol-Myers Squibb and Hybridon, Inc. Dr. Slichenmyer holds a BA and a MD from Case Western Reserve University as well as a Sc.M. from the Schools of Medicine and Public Health at The Johns Hopkins University. He is a board certified Medical Oncologist, having completed his Oncology fellowship training at The Johns Hopkins Oncology Center. | 